一种新的口服脱毛药物VDPHL01显示,在第三阶段试验中,男女在安全、有效重生头发方面有希望。 A new oral hair loss drug, VDPHL01, shows promise in phase three trials for safe, effective hair regrowth in men and women.

一种新的口服丧失毛发药物VDPHL01,由Verdermics研制,目前处于第三阶段试验阶段,有可能是林业发展局批准的对男子和妇女的首次延长释放分氧化物的治疗。 A new oral hair loss drug, VDPHL01, developed by Veradermics, is in phase three trials as a potential first FDA-approved extended-release minoxidil treatment for both men and women. 旨在缓慢释放药物,旨在改善头发生长,同时降低与非标签口服米诺克西德相关的心血管风险. Designed to release the drug slowly, it aims to improve hair growth while reducing cardiovascular risks linked to off-label oral minoxidil. 这些审判涉及约1 500名参与者,包括跨越多个地点的双盲测试,预计2026年将完成对男子和妇女的审判。 The trials, involving about 1,500 participants, include double-blind testing across multiple sites and are expected to conclude in 2026 for men and shortly after for women. 早期结果显示,在短短两个月的时间里,头发计数明显增加,并出现明显的再增长,没有观察到严重的心脏副作用。 Early results show significant hair count increases and visible regrowth in as little as two months, with no serious cardiac side effects observed. 如果获得批准,它可以为目前的治疗提供一种更安全、具有性别包容性的替代方案。 If approved, it could offer a safer, gender-inclusive alternative to current treatments.